The invention relates to a method of administering a fatty acid-acylated insulin or insulin analog by inhalation, a method for treating diabetes by administering a fatty acid-acylated insulin or insul
11. A method of delivering a fatty acid-acylated human insulin or fatty acid-acylated human insulin analog, comprising the step of using an inhalation device to deposit in the lungs of a patient in need thereof an effective amount of a pharmaceutical formulation comprising a fatty acid-acylated ...
摘要: Novel methods of using thiazolidinone derivatives and related antihyperglycemic agents to treat populations experiencing impaired glucose intolerance in order to prevent or delay the onset of noninsulin-dependent diabetes mellitus (NIDDM) and complications arising therefrom are disclosed....
A preferred inhibitor of VEGF-mediated activity is a VEGF antagonist such as the VEGF fusion protein trap of SEQ ID NO:2 capable of binding and blocking VEGF. The method of the invention may be combined with other therapies, such as with insulin therapy. ...
herein, the terms further include any physiologically or pharmacologically active substance that produces a localized or systemic effect or effects in animals, including warm blooded mammals, humans and primates; avians; domestic household or farm animals such as cats, dogs, sheep, goats, cattle, ...
insulin, triiodotyronine, dopamine, a vasopressor agent, such as desmopressin, and methylprednisolone. The composition may be dissolved in pure water, Ringer's acetate solution or physiological sodium chloride solution. The composition is infused in such an amount as to maintain a mean arterial press...
Diabetes mellitus is a chronic disease with disordered metabolisms of carbohydrates, fats and proteins caused by relatively or absolutely insufficient insulin in the body or decreased sensitivity of target cells to insulin, or structural defects in insulin itself[1]. The annual cost for the treatment...